Connection

Weijin Huang to Humans

This is a "connection" page, showing publications Weijin Huang has written about Humans.
Connection Strength

0.072
  1. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021; 12:687869.
    View in: PubMed
    Score: 0.008
  2. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerg Microbes Infect. 2021 Dec; 10(1):1390-1403.
    View in: PubMed
    Score: 0.002
  3. Lentil lectin derived from Lens culinaris exhibit broad antiviral activities against SARS-CoV-2 variants. Emerg Microbes Infect. 2021 Dec; 10(1):1519-1529.
    View in: PubMed
    Score: 0.002
  4. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerg Microbes Infect. 2021 Dec; 10(1):1574-1588.
    View in: PubMed
    Score: 0.002
  5. Polyketone metabolites isolated from Rhodiola tibetica endohytic fungus Alternaria sp. HJT-Y7 and their SARS-CoV-2 virus inhibitory activitives. Bioorg Chem. 2021 11; 116:105309.
    View in: PubMed
    Score: 0.002
  6. Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. Cell Res. 2021 10; 31(10):1130-1133.
    View in: PubMed
    Score: 0.002
  7. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021 08 17; 12(1):5000.
    View in: PubMed
    Score: 0.002
  8. Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. Bioorg Chem. 2021 10; 115:105196.
    View in: PubMed
    Score: 0.002
  9. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021 07 09; 12(1):4210.
    View in: PubMed
    Score: 0.002
  10. The molecular basis for SARS-CoV-2 binding to dog ACE2. Nat Commun. 2021 07 07; 12(1):4195.
    View in: PubMed
    Score: 0.002
  11. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021 07; 31(7):732-741.
    View in: PubMed
    Score: 0.002
  12. The first Chinese national standards for SARS-CoV-2 neutralizing antibody. Vaccine. 2021 06 23; 39(28):3724-3730.
    View in: PubMed
    Score: 0.002
  13. Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. Signal Transduct Target Ther. 2021 05 17; 6(1):196.
    View in: PubMed
    Score: 0.002
  14. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28; 134(11):1289-1298.
    View in: PubMed
    Score: 0.002
  15. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 03 27; 6(1):134.
    View in: PubMed
    Score: 0.002
  16. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021 03 01; 12(1):1346.
    View in: PubMed
    Score: 0.002
  17. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 04 29; 184(9):2362-2371.e9.
    View in: PubMed
    Score: 0.002
  18. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020 Dec; 9(1):680-686.
    View in: PubMed
    Score: 0.002
  19. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat Microbiol. 2021 01; 6(1):51-58.
    View in: PubMed
    Score: 0.002
  20. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020 11 13; 11(1):5752.
    View in: PubMed
    Score: 0.002
  21. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
    View in: PubMed
    Score: 0.002
  22. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front Med. 2020 Dec; 14(6):746-751.
    View in: PubMed
    Score: 0.002
  23. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020 11; 15(11):3699-3715.
    View in: PubMed
    Score: 0.002
  24. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020 10; 586(7830):572-577.
    View in: PubMed
    Score: 0.002
  25. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020 09 18; 369(6510):1505-1509.
    View in: PubMed
    Score: 0.002
  26. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020 09 03; 182(5):1271-1283.e16.
    View in: PubMed
    Score: 0.002
  27. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020 09 03; 182(5):1284-1294.e9.
    View in: PubMed
    Score: 0.002
  28. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020 09; 81(3):420-426.
    View in: PubMed
    Score: 0.002
  29. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020 08; 584(7819):120-124.
    View in: PubMed
    Score: 0.002
  30. Absence of hepatitis E virus RNA in semen samples of infertile male in China. Gut. 2020 07; 69(7):1363-1364.
    View in: PubMed
    Score: 0.002
  31. Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin. J Infect Dis. 2019 01 01; 219(1):19-25.
    View in: PubMed
    Score: 0.002
  32. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. Emerg Microbes Infect. 2019; 8(1):272-281.
    View in: PubMed
    Score: 0.002
  33. Hepatitis E virus was not detected in feces and milk of cows in Hebei province of China: No evidence for HEV prevalence in cows. Int J Food Microbiol. 2019 Feb 16; 291:5-9.
    View in: PubMed
    Score: 0.002
  34. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018 08 23; 10(9).
    View in: PubMed
    Score: 0.002
  35. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018 01; 28(1).
    View in: PubMed
    Score: 0.001
  36. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccin Immunother. 2018 01 02; 14(1):199-208.
    View in: PubMed
    Score: 0.001
  37. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep. 2017 03 30; 7:45552.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.